Literature DB >> 17475216

Dendroaspis natriuretic peptide binds to the natriuretic peptide clearance receptor.

Douglas G Johns1, Zhaohui Ao, Bradley J Heidrich, Gerald E Hunsberger, Taylor Graham, Lisa Payne, Nabil Elshourbagy, Quinn Lu, Nambi Aiyar, Stephen A Douglas.   

Abstract

Dendroaspis natriuretic peptide (DNP) is a newly-described natriuretic peptide which lowers blood pressure via vasodilation. The natriuretic peptide clearance receptor (NPR-C) removes natriuretic peptides from the circulation, but whether DNP interacts with human NPR-C directly is unknown. The purpose of this study was to test the hypothesis that DNP binds to NPR-C. ANP, BNP, CNP, and the NPR-C ligands AP-811 and cANP(4-23) displaced [(125)I]-ANP from NPR-C with pM-to-nM K(i) values. DNP displaced [(125)I]-ANP from NPR-C with nM potency, which represents the first direct demonstration of binding of DNP to human NPR-C. DNP showed high pM affinity for the GC-A receptor and no affinity for GC-B (K(i)>1000 nM). DNP was nearly 10-fold more potent than ANP at stimulating cGMP production in GC-A expressing cells. Blockade of NPR-C might represent a novel therapeutic approach in augmenting the known beneficial actions of DNP in cardiovascular diseases such as hypertension and heart failure.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17475216     DOI: 10.1016/j.bbrc.2007.04.079

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  15 in total

1.  Differential activation of natriuretic peptide receptors modulates cardiomyocyte proliferation during development.

Authors:  Jason R Becker; Sneha Chatterjee; Tamara Y Robinson; Jeffrey S Bennett; Daniela Panáková; Cristi L Galindo; Lin Zhong; Jordan T Shin; Shannon M Coy; Amy E Kelly; Dan M Roden; Chee Chew Lim; Calum A MacRae
Journal:  Development       Date:  2013-12-18       Impact factor: 6.868

2.  New insights and new hope for pulmonary arterial hypertension: natriuretic peptides clearance receptor as a novel therapeutic target for a complex disease.

Authors:  Emmanuel Eroume-A Egom; Tiam Feridooni; Rebabonye B Pharithi; Barkat Khan; Haaris A Shiwani; Vincent Maher; Yassine El Hiani; Robert A Rose; Kishore Bs Pasumarthi; Hilaire A Ribama
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2017-09-01

Review 3.  CD-NP: an innovative designer natriuretic peptide activator of particulate guanylyl cyclase receptors for cardiorenal disease.

Authors:  Paul M McKie; S Jeson Sangaralingham; John C Burnett
Journal:  Curr Heart Fail Rep       Date:  2010-09

4.  Electrophysiologic and molecular mechanisms of a frameshift NPPA mutation linked with familial atrial fibrillation.

Authors:  Ambili Menon; Liang Hong; Eleonora Savio-Galimberti; Arvind Sridhar; Seock-Won Youn; Meihong Zhang; Kaylen Kor; Marcia Blair; Sabina Kupershmidt; Dawood Darbar
Journal:  J Mol Cell Cardiol       Date:  2019-05-08       Impact factor: 5.000

5.  C53: A novel particulate guanylyl cyclase B receptor activator that has sustained activity in vivo with anti-fibrotic actions in human cardiac and renal fibroblasts.

Authors:  Yang Chen; Ye Zheng; Seethalakshmi R Iyer; Gerald E Harders; Shuchong Pan; Horng H Chen; Tomoko Ichiki; John C Burnett; S Jeson Sangaralingham
Journal:  J Mol Cell Cardiol       Date:  2019-04-04       Impact factor: 5.000

6.  Transcriptomic analysis of the venom gland of the red-headed krait (Bungarus flaviceps) using expressed sequence tags.

Authors:  Ang Swee Siang; Robin Doley; Freek J Vonk; R Manjunatha Kini
Journal:  BMC Mol Biol       Date:  2010-03-29       Impact factor: 2.946

Review 7.  Modulation of cGMP in heart failure: a new therapeutic paradigm.

Authors:  Guido Boerrigter; Harald Lapp; John C Burnett
Journal:  Handb Exp Pharmacol       Date:  2009

8.  Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation.

Authors:  Denice M Hodgson-Zingman; Margaret L Karst; Leonid V Zingman; Denise M Heublein; Dawood Darbar; Kathleen J Herron; Jeffrey D Ballew; Mariza de Andrade; John C Burnett; Timothy M Olson
Journal:  N Engl J Med       Date:  2008-07-10       Impact factor: 91.245

9.  Novel bifunctional natriuretic peptides as potential therapeutics.

Authors:  Deborah M Dickey; John C Burnett; Lincoln R Potter
Journal:  J Biol Chem       Date:  2008-10-21       Impact factor: 5.157

10.  Cardiac natriuretic peptide deficiency sensitizes the heart to stress-induced ventricular arrhythmias via impaired CREB signalling.

Authors:  Eric J Hall; Soumojit Pal; Michael S Glennon; Puneeth Shridhar; Sidney L Satterfield; Beth Weber; Qinkun Zhang; Guy Salama; Hind Lal; Jason R Becker
Journal:  Cardiovasc Res       Date:  2022-07-20       Impact factor: 13.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.